<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        46-334-00
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2000
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        OMNICEF 300MG CAPSULE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CEFDINIR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        300
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        79.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jazeera Pharmaceutical Industries (JPI)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DD15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cefdinir is in a group of drugs called cephalosporin antibiotics. It works by fighting bacteria in your body.</p><p>Cefdinir is used to treat many different types of infections caused by bacteria.</p><p>Cefdinir may also be used for purposes not listed in this medication guide.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Omnicef&reg;</strong></p><p>You are allergic to cefdinir, or to similar antibiotics, such as other cephalosporin antibiotic:</p><ul><li>cefaclor;</li><li>cefadroxil;</li><li>cefazolin;</li><li>cefditoren;</li><li>cefpodoxime;</li><li>cefprozil;</li><li>ceftibuten;</li><li>cefuroxime;</li><li>cephalexin; or</li><li>cephradine; and others.</li></ul><p><strong>Take special care and tell your doctor if you have any of these other conditions:</strong></p><ul><li>kidney disease (or if you are on dialysis);</li><li>a history of intestinal problems, such as colitis; or</li><li>if you are allergic to any drugs (especially penicillins).</li></ul><p><strong>Warnings and precautions</strong></p><ul><li>Take this medication for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Skipping doses may also increase your risk of further infection that is resistant to antibiotics. Cefdinir will not treat a viral infection such as the common cold or flu.</li><li>Antibiotic medicines can cause diarrhea, which may be a sign of a new infection. If you have diarrhea that is watery or bloody, stop taking cefdinir and call your doctor. Do not use anti-diarrhea medicine unless your doctor tells you to.</li><li>This medication can cause you to have false results with certain medical tests, including urine glucose (sugar) tests. Tell any doctor who treats you that you are using cefdinir.</li><li>Avoid using antacids or mineral supplements that contain iron within 2 hours before or after taking cefdinir. Antacids or iron can make it harder for your body to absorb cefdinir. <strong>This does not include baby formula fortified with iron.</strong></li><li>Taking cefdinir with products that contain iron may cause your stools (bowel movements) to appear red in color. If this discoloration looks like blood in your stools, call your doctor.</li></ul><p><strong>Other medicines and Omnicef&reg;</strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.</p><p>Tell your doctor about all other medications you use, especially:</p><ul><li>Probenecid; a medicament used to treat gout or;</li><li>vitamin or mineral supplements that contain iron.</li></ul><p>This list is not complete and other drugs may interact with cefdinir. Tell your doctor about all medications you use.</p><p><strong>Omnicef&reg; with food and drink</strong></p><p>You may take this medication with or without food.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>This medication is not expected to be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment.</p><p>It is not known whether cefdinir passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.</p><p><strong>Omnicef&reg; suspension contains Sugar</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Omnicef&reg; exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>Take this medication by mouth, with or without food, usually once a day, or twice a day every 12 hours, or as directed by your doctor.</p><p>The dosage is based on your medical condition and response to therapy. Do not take more than the maximum recommended amount of 600 milligrams per day.</p><p>Shake the <strong>oral suspension (liquid) </strong>well just before you measure a dose. To be sure you get the correct dose, measure the liquid with a marked measuring spoon or medicine cup, not with a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.</p><p><strong>If you take more Omnicef&reg; than you should</strong></p><p>If you have accidentally taken too much Omnicef&reg;, contact your doctor or nearest hospital emergency department immediately.</p><p>Overdose symptoms may include nausea, vomiting, stomach pain, and diarrhea.</p><p><strong>If you forget to take Omnicef&reg;</strong></p><p>Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. <strong>Do not </strong>take extra medicine to make up the missed dose.</p><p><strong>If you stop taking Omnicef&reg;</strong></p><p>Continue to use this medication until the full prescribed amount is finished even if symptoms disappear after a few days. Stopping the medication too early may allow bacteria to continue to grow, which may result in a relapse of the infection.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines Omnicef&reg; can cause side effects, although not everybody gets them.</p><p>Get emergency medical help if you have any of these <strong>signs of an allergic reaction:</strong></p><p>Hives; difficulty breathing; swelling of your face, lips, tongue, or throat.</p><p><strong>Call your doctor at once if you have any of these serious side effects:</strong></p><ul><li>diarrhea that is watery or bloody;</li><li>chest pain;</li><li>fever, chills, body aches, flu symptoms;</li><li>unusual bleeding;</li><li>seizure (convulsions);</li><li>&nbsp;pale or yellowed skin, dark colored urine, fever, confusion or weakness;</li><li>jaundice (yellowing of the skin or eyes);</li><li>fever, sore throat, and headache with a severe blistering, peeling, and red skin rash; or</li><li>increased thirst, loss of appetite, swelling, weight gain, feeling short of breath, urinating less than usual or not at all.</li></ul><p><strong>Less serious side effects may include:</strong></p><ul><li>nausea, stomach pain, indigestion, vomiting, mild diarrhea;</li><li>headache, dizziness;</li><li>diaper rash in an infant taking liquid cefdinir;</li><li>mild itching or skin rash; or</li><li>vaginal itching or discharge.</li></ul><p>This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to SFDA as in section 6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><ul><li>Keep out of the sight and reach of children.</li><li>Do not use Omnicef&reg; after the expiry date which is stated on the carton after &ldquo;Exp&rdquo;. The expiry date refers to the last day of that month.</li><li>Store below 30&deg;C away from moisture and heat. Throw away any unused Omnecif liquid that is older than 10 days.</li><li>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Cefdinir.</p><p>Each <strong>capsule </strong>of Omnicef&reg; 300 mg contains 300 mg of Cefdinir. The other ingredients are: Carmellose Calcium and Treated Magnesium Stearate</p><p>Each 5 ml from Omnicef <strong>suspension </strong>contains 125 mg of Cefdinir. The other ingredients are: Citric Acid Anhydrous; Sodium Benzoate; Trisodium Citrate Anhydrous; Guar gum; Xanthum gum; Strawberry Flavour; Magnesiun Stearate; Aerosil-200; Sugar Crystalline.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Omnicef® 300 mg capsules are consists of Body of the capsule: Flesh color and Cap of the capsule:
Flesh color, capsule size: 1, imprinted with “JPI011” on cap and body, inside capsule there is pale yellowish white powder or granules.
Omnicef® 300 mg is supplied in a jar containing 10 capsules.
Omnicef® 125 mg/ 5 ml suspension are pale yellow suspension with strawberry falvour.
Omnicef® 125 mg/ 5 ml suspension is supplied in a bottle containing 40 or 80 ml.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u>Marketing Authorisation Holder:</u></p><p>Jazeera Pharmaceutical Industries (JPI)</p><p>Riyadh, Saudi Arabia, 11666 Riyadh, P.O.Box 106229</p><p>Phone No.: +966-11-207-8172</p><p>Fax: +966-11-207-8097</p><p>E-mail: <u>medical@jpi.com.sa</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 11/2014, version 1.0
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي أومنيسف لمجموعة من الأدوية تسمى مضادات السيفالوسبورين الحيوية. وهو يعمل عن طريق محاربة البكتيريا في الجسم.<br />يستخدم أومنيسف لعلاج العديد من أنواع مختلفة من الالتهابات التي تسببها البكتيريا.<br />يمكن أيضاً أن يستخدم لأغراض غير مدرجة في هذا الدليل الدوائي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع إستعمال أومنيسف</strong><strong>:</strong></p><p dir="RTL">لا تستخدم أومنيسف:</p><p dir="RTL">إذا كان لديك حساسية من سيفدينير، أو للمضادات الحيوية المشابهة، مثل غيرها من مضادات السيفالوسبورين الحيوية:</p><ul dir="rtl"><li>سيفاكلور</li><li>سيفادروكسيل</li><li>سيفازولين</li><li>سيفديتورين</li><li>سيفبودوكسيم</li><li>سيفبروزيل</li><li>سيفتيبيوتين</li><li>سيفوروكسيم</li><li>سيفالكسين</li><li>سيفرادين أو غيرها.</li></ul><p dir="RTL"><strong>الاحتياطات عند استخدام أومنيسف</strong><strong>:</strong></p><p dir="RTL">يجب استشارة طبيبك قبل إستخدام أومنيسف. في الحالات التالية:</p><ul dir="rtl"><li>أمراض الكلى (أو إذا كنت تقوم بغسيل الكلى)</li><li>تاريخ من مشاكل معوية، مثل التهاب القولون</li><li>إذا كنت تعاني من حساسية لأي دواء (وخاصة البنسلين).</li></ul><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><ul dir="rtl"><li>خذ هذا الدواء للمدة المقررة كاملة. قد تتحسن الأعراض الخاصة بك قبل شفاء الإلتهاب تماما. &nbsp;يزيد تخطي الجرعات أيضا من خطر مزيد من العدوى التي هي مقاومة للمضادات الحيوية. لن يعالج سيفدينير العدوى الفيروسية مثل الانفلونزا أو البرد الشائع.</li><li>أدوية المضادات الحيوية يمكن أن تسبب الإسهال، والذي قد يكون علامة على وجود عدوى جديدة. إذا كنت تعاني من الإسهال المائي او الدموي توقف عن تناول سيفدينير واستدعي الطبيب. لا تستخدم الأدوية المضادة للإسهال، ما لم يخبرك طبيبك بذلك.</li><li>هذا الدواء يمكن أن يسبب لك الحصول على نتائج خاطئة مع بعض الفحوصات الطبية، بما في ذلك فحوصات غلوكوز البول (السكر). أخبر الطبيب الذي يعالجك أنك تستخدم سيفدينير.</li><li>تجنب استخدام مضادات الحموضة أو المكملات المعدنية التي تحتوي على الحديد خلال 2 ساعة قبل أو بعد أخذ سيفدينير. يمكن أن تجعل مضادات الحموضة أو الحديد من الصعب على جسمك امتصاص سيفدينير. وهذا لا يشمل حليب الأطفال المدعم بالحديد.</li><li>اخذ سيفدينير مع المنتجات التي تحتوي على الحديد قد يسبب أن يكون البراز أحمر اللون. إذا كان هذا اللون يشبه الدم في البراز، استدعي الطبيب<strong>.</strong></li></ul><p dir="RTL"><strong>التداخلات الدوائية مع الأدوية الأخرى أو الأعشاب أوالمكملات الغذائية</strong></p><p dir="RTL">يجب إستشارة طبيبك أو الصيدلي قبل إستخدام أومنيسف إذا كنت تأخذ أو أخذت مؤخر اً أية أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها بدون وصفة طبية أو الفيتامينات أو الأعشاب. قد تتأثر هذه الأدوية في أومنيسف أو قد يؤثر في حسن أداءها. قد تحتاج إلى كميات مختلفة من الأدوية الخاصة بك، أو قد تحتاج إلى تناول أدوية مختلفة، خاصة إذا كنت تأخذ:</p><ul dir="rtl"><li>البروبنيسيد، وهو دواء يستخدم لعلاج النقرس أو</li><li>الفيتامينات أو مكملات المعادن الغذائية التي تحتوي على الحديد.</li></ul><p dir="RTL">هذه القائمة ليست كاملة وقد تتفاعل غيرها من الأدوية مع سيفدينير. أخبر طبيبك عن جميع الأدوية التي تستخدمها.</p><p dir="RTL"><strong>تناول أومنيسف مع الطعام والشرا</strong><strong>ب</strong></p><p dir="RTL">تستطيع تناول أومنيسف مع أو بدون الطعام</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">من غير المتوقع أن يكون أومنيسف ضار ا للجنين. أخبر طبيبك إذا كنت حاملا أو تخططين لتصبحي حاملا أثناء العلاج.</p><p dir="RTL">من غير المعروف ما إذا كان سيفدينير يفرز في حليب الثدي أو إذا كان يمكن أن يضر برضاعة الطفل. لا تستخدمي هذا الدواء دون ابلاغ طبيبك إذا كنت ترضعين رضاعة طبيعية.</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات أومنيسف</strong></p><p dir="RTL">يحتوي أومنيسف على السكر. يرجى إستشارة طبيبك قبل إستخدامه إذا أخبرك أنك تعاني من عدم احتمال السكريات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يرجى استخدام أومنيسف تماما&nbsp;كما وصفه الطبيب أو استشارة الطبيب أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL">خذ هذا الدواء عن طريق الفم، مع او بدون الطعام، وعادة مرة واحدة يوميا، أو مرتين في اليوم كل 12 ساعة، أو حسب توجيهات الطبيب.</p><p dir="RTL">تبنى الجرعه على اساس الحاله الصحية الخاصة بك واستجابتك للعلاج. لا تأخذ أكثر من الحد الأقصى للكمية الموصى بها 600 ملجم في اليوم الواحد.</p><p dir="RTL">رج المعلق الفموي (السائل) جيد اً قبل قياس الجرعة. للتأكد من حصولك على الجرعة الصحيحة، قم بقياس السائل بملعقة مقاسات أو كأس دواء، وليس بملعقة الطعام العادية. إذا لم يكن لديك جهاز قياس الجرعة، اسأل الصيدلي عن واحد.</p><p dir="RTL"><strong>الجرعة الزائدة من أومنيسف</strong></p><p dir="RTL">إذا كنت قد اخذ الكثير من أومنيسف دون قصد، اتصل بطبيبك أو أقرب قسم طوارئ في المستشفى على الفور.</p><p dir="RTL">يمكن أن تشمل أعراض الجرعة الزائدة الغثيان، والتقيؤ، آلام في المعدة، والإسهال.</p><p dir="RTL"><strong>نسيان تناول جرعة أومنيسف</strong></p><p dir="RTL">خذ الجرعة المنسية في أقرب وقت تذكر فيه. تخطى الجرعة المنسية إذا كان الوقت تقريباً قد حان لتناول الجرعة القادمة حسب الجدول الزمني الخاص بك. لا تأخذ جرعة دواء اضافية لتعويض الجرعة المنسية.</p><p dir="RTL"><strong>التوقف عن استخدام أومنيسف</strong></p><p dir="RTL">استمر في استخدام هذا الدواء حتى يتم الانتهاء من كامل الجرعة المنصوص عليها حتى لو اختفت الأعراض بعد بضعة أيام. وقف الدواء في وقت مبكر جداً قد يسمح للبكتيريا ان تستمر في النمو، مما قد يؤدي الى انتكاسة الالتهاب.</p><p dir="RTL">للاستفسار أو المزيد من المعلومات عن إستخدام هذا الدواء، يرجى إستشارة الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية بعض المرضى قد يعانون من أعراض جانبية معينة.</p><p dir="RTL">احصل على المساعدة الطبية في حالات الطوارئ إذا شعرت بأي من هذه العلامات الحساسية:</p><p dir="RTL">الشرى؛ صعوبة في التنفس؛ تورم وجهك، والشفتين واللسان، أو الحلق.</p><p dir="RTL">استدعي الطبيب على الفور إذا كان لديك أي من هذه الآثار الجانبية الخطيرة:</p><ul dir="rtl"><li>الإسهال المائي او الدموي.</li><li>&nbsp;ألم الصدر</li><li>الحمى والقشعريرة وآلام الجسم، وأعراض الانفلونزا.</li><li>نزيف غير عادي.</li><li>نوبات (تشنجات)</li><li>الجلد الشاحب المصفر، والبول قاتم اللون، والحمى، والارتباك أو الضعف</li><li>اليرقان (اصفرار الجلد أو العينين )</li><li>الحمى، والتهاب الحلق، وصداع شديد، تقشير، واحمرار الجلد وطفح جلدي</li><li>زيادة العطش، وفقدان الشهية، وتورم، وزيادة الوزن، والشعور بضيق التنفس، والتبول أقل من المعتاد أو عدم التبول على الاطلاق.</li></ul><p dir="RTL"><strong>يمكن أن تشمل الآثار الجانبية الأقل خطورة</strong><strong>:</strong></p><ul dir="rtl"><li>الغثيان وآلام في المعدة، وعسر الهضم والقيء وإسهال خفيف.</li><li>الصداع، والدوخة</li><li>طفح من حفاضات الرضع الذين يأخذون سيفدينير السائل</li><li>حكة خفيفة أو طفح جلدي</li><li>الحكة أوالإفرازات المهبلية</li></ul><p dir="RTL">هذه ليست قائمة كاملة من الاثار الجانبية وقد يحدث غيرها. أخبر طبيبك عن أي آثار جانبية غير عادية أو مزعجة. يمكنك الإبلاغ عن الآثار الجانبية لهيئة الغذاء والدواء حسب القسم 6.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إحفظ هذا الدواء بعيدا عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تحفظ الدواء عند درجة حرارة أعلى من 30 &deg;مئوية</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العلبة الخارجية.</p><p dir="RTL">يشير تاريخ الإنتهاء إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة اليها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي سيفدينير</p><p dir="RTL">تحتوي كل كبسولة من أومنيسف على 300 ملجم من سيفدينير.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي كارميلوز الكالسيوم، وستيرات الملجمنيسيوم المعالج.</p><p dir="RTL">يحتوي كل 5 مل من أومنيسف المعلق على 125 ملجم من سيفدنير.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي حمض الستريك اللامائي، بنزوات الصوديوم، سترات الصوديوم اللامائية، صملجم الغار، صملجم زنتان، نكهة الفراولة، ستيرات الملجمنيسيوم، أيروسيل 200, سكر بلوري.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو الشكل الصيدلاني لأومنيسف ووصفه و حجم عبوته</strong></p><p dir="RTL">أومنيسف 300 ملجم كبسولات يتكون جسم الكبسولة من: لون اللحم وغطاء الكبسولة: لون لحمي، حجم الكبسولة: 1، مطبوع عليها</p><p dir="RTL">&quot;JPI011&quot; على الغطاء والجسم، وداخل الكبسولة هناك مسحوق أبيض مصفر أو حبيبات.</p><p dir="RTL">يتوفر أومنيسف 300 ملجم في جرة تحتوي على 10 كبسولات.</p><p dir="RTL">معلق أومنيسف 125 ملجم/ 5مل يحتوي على معلق أصفر شاحب مع نكهة الفراولة.</p><p dir="RTL">يتوفر أومنيسف 125 ملجم/ 5مل معلق في زجاجة تحتوي على 40 أو 80 مل<strong>.</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الجزيرة للصناعات الدوائية<br />الرياض، السعودية، 11666 الرياض، صندوق بريد 106229<br />هاتف: 966112078172<br />فاكس: 966112078097<br />البريد الإلكتروني: <u>medical@jpi.com.sa</u></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت الموافقة على هذه النشرة بتاريخ 04/2016 , نسخة رقم 1.1
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Omnicef 300 mg Capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                OMNICEF Capsules contain 300 mg cefdinir.
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Capsules;
Body: Flesh color, cap: Flesh color, capsule size: 1, imprinted with “JPI011” on cap and body,
containing pale yellowish white powder or granules.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>OMNICEF (cefdinir) capsules and OMNICEF (cefdinir) for oral suspension are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below.</p><p><strong><em><u>Adults and Adolescents</u></em></strong></p><p><strong><em>&nbsp;</em></strong><em>Community-Acquired Pneumonia </em>caused by Haemophilus influenzae (including &beta;-lactamase producing strains), Haemophilus parainfluenzae (including &beta;-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including &beta;lactamase producing strains)</p><p><em>Acute Exacerbations of Chronic Bronchitis </em>caused by Haemophilus influenzae (including &beta;- lactamase producing strains), Haemophilus parainfluenzae (including &beta;-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including &beta;lactamase producing strains).</p><p><em>Acute Maxillary Sinusitis </em>caused by Haemophilus influenzae (including &beta;-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including &beta;-lactamase producing strains).</p><p><strong><em>NOTE: </em></strong>For information on use in pediatric patients, see Pediatric Use ( section 4.2: Posology and method of administration).</p><p><em>Pharyngitis/Tonsillitis </em>caused by Streptococcus pyogenes.</p><p><strong><em>NOTE: </em></strong>Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever.</p><p><em>Uncomplicated Skin and Skin Structure Infections </em>caused by Staphylococcus aureus (including &beta;- lactamase producing strains) and Streptococcus pyogenes.</p><p><strong><em><u>Pediatric Patients</u></em></strong></p><p>Acute Bacterial Otitis Media caused by Haemophilus influenzae (including &beta;-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including &beta;-lactamase producing strains).</p><p><em>Pharyngitis/Tonsillitis </em>caused by Streptococcus pyogenes.</p><p><strong><em>NOTE: </em></strong>Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever.</p><p><em>Uncomplicated Skin and Skin Structure Infections </em>caused by Staphylococcus aureus (including &beta;- lactamase producing strains) and Streptococcus pyogenes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>(see section 4.1: Therapeutic indication for Indicated Pathogens)</p><p><strong>Capsules</strong></p><p>The recommended dosage and duration of treatment for infections in adults and adolescents are described in the following chart; the total daily dose for all infections is 600 mg. Once-daily dosing for 10 days is as effective as BID dosing. Once-daily dosing has not been studied in pneumonia or skin infections; therefore, OMNICEF Capsules should be administered twice daily in these infections. OMNICEF Capsules may be taken without regard to meals.</p><p><strong>Table 1: Adults and Adolescents (Age 13 Years and Older)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:454px"><tbody><tr><td><p><strong>Type of infection</strong></p></td><td><p><strong>Dosage</strong></p></td><td style="width:101px"><p><strong>Duration</strong></p></td></tr><tr><td><p>Community-Acquired Pneumonia</p></td><td><p>300 mg q12h</p></td><td style="width:101px"><p>10 days</p></td></tr><tr><td><p>Acute Exacerbations of Chronic Bronchitis</p></td><td><p>&nbsp;</p><p>300 mg q12h</p><p>or</p><p>600 mg q24h</p></td><td style="width:101px"><p>&nbsp;</p><p>5 to 10 days</p><p>&nbsp;</p><p>10 days</p></td></tr><tr><td><p>&nbsp;</p><p>Acute Maxillary Sinusitis</p></td><td><p>300 mg q12h</p><p>or</p><p>600 mg q24h</p></td><td style="width:101px"><p>10 days</p><p>&nbsp;</p><p>10 days</p></td></tr><tr><td><p>&nbsp;</p><p>Pharyngitis/Tonsillitis</p><p>&nbsp;</p><p>&nbsp;</p></td><td><p>300 mg q12h</p><p>or</p><p>600 mg q24h</p></td><td style="width:101px"><p>5 to 10 days</p><p>&nbsp;</p><p>10 days</p></td></tr><tr><td><p>Uncomplicated Skin and Skin Structure</p><p>Infections</p></td><td><p>300 mg q12h</p></td><td style="width:101px"><p>10 days</p></td></tr></tbody></table><p><strong>Powder for Oral Suspension</strong></p><p>The recommended dosage and duration of treatment for infections in pediatric patients are described in the following chart; the total daily dose for all infections is 14 mg/kg, up to a maximum dose of 600 mg per day. Once-daily dosing for 10 days is as effective as BID dosing. Once-daily dosing has not been studied in skin infections; therefore, OMNICEF for Oral Suspension should be administered twice daily in this infection. OMNICEF for Oral Suspension may be administered without regard to meals.</p><p><strong>Table 2: Pediatric Patients (Age 6 Months Through 12 Years)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Type of infection</strong></p></td><td><p><strong>Dosage</strong></p></td><td><p><strong>Duration</strong></p></td></tr><tr><td><p>&nbsp;</p><p>Acute Bacterial Otitis Media</p></td><td><p>7 mg/kg q12h &nbsp;&nbsp;&nbsp;&nbsp;or</p><p>14 mg/kg q24h</p></td><td><p>5 to 10 days</p><p>10 days</p></td></tr><tr><td><p>&nbsp;</p><p>Acute Maxillary Sinusitis</p></td><td><p>7 mg/kg q12h &nbsp;&nbsp;&nbsp;or</p><p>14 mg/kg q24h</p></td><td><p>10 days</p><p>10 days</p></td></tr><tr><td><p>&nbsp;</p><p>Pharyngitis/Tonsillitis</p></td><td><p>7 mg/kg q12h or</p><p>14 mg/kg q24h</p></td><td><p>10 days</p><p>5 to 10 days</p></td></tr><tr><td><p>Uncomplicated Skin and Skin Structure Infections</p></td><td><p>7 mg/kg q12h</p></td><td><p>10 days</p></td></tr></tbody></table><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p><p><strong>Table 3: OMNICEF FOR ORAL SUSPENSION PEDIATRIC DOSAGE CHART</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Weight</p></td><td><p>125 mg/5 mL</p></td></tr><tr><td><p>9 kg/20 lbs</p></td><td><p>2.5 mL q12h or 5 mL q24h</p></td></tr><tr><td><p>18 kg/40 lbs</p></td><td><p>5 mL q12h or 10 mL q24h</p></td></tr><tr><td><p>27 kg/60 lbs</p></td><td><p>7.5 mL q12h or 15 mL q24h</p></td></tr><tr><td><p>36 kg/80 lbs</p></td><td><p>10 mL q12h or 20 mL q24h</p></td></tr><tr><td><p>&ge;43 kg<sup>a</sup>/95 lbs</p></td><td><p>12 mL q12h or 24 mL q24h</p></td></tr></tbody></table><p><sup>a</sup>Pediatric patients who weigh &ge; 43 kg should receive the maximum daily dose of 600 mg.</p><p><strong>Patients With Renal Insufficiency</strong></p><p>For adult patients with creatinine clearance &lt; 30 mL/min, the dose of cefdinir should be 300 mg given once daily.</p><p>Creatinine clearance is difficult to measure in outpatients. However, the following formula may be used to estimate creatinine clearance (CLcr) in adult patients. For estimates to be valid, serum creatinine levels should reflect steady-state levels of renal function.</p><p>Males: 𝐶𝑙𝑐𝑟 = (weight)(140&minus;age) /(72)(𝑠𝑒𝑟𝑢𝑚 𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒)</p><p>Females: 𝐶𝑙𝑐𝑟 = 0.85 𝑥 𝑚𝑎𝑙𝑒 𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒 𝑐𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒 (𝑎𝑏𝑜𝑣𝑒 𝑣𝑎𝑙𝑢𝑒)</p><p>where creatinine clearance is in <strong>mL/min</strong>, age is in <strong>years</strong>, weight is in <strong>kilograms</strong>, and serum creatinine is in <strong>mg/dL<sup>(3)</sup></strong><sup>.</sup></p><p>The following formula may be used to estimate creatinine clearance in <strong>pediatric patients</strong>:</p><p>𝐶𝑙𝑐𝑟 = K x&nbsp; (body length or height / 𝑠𝑒𝑟𝑢𝑚 𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒)</p><p>where K = 0.55 for pediatric patients older than 1 year<sup>(4) </sup>&nbsp;and 0.45 for infants (up to 1 year)<sup>(5)</sup>.</p><p>In the above equation, creatinine clearance is in mL/min/1.73 m<sup>2</sup>, body length or height is in centimeters, and serum creatinine is in mg/dL.</p><p>For pediatric patients with a creatinine clearance of &lt; 30 mL/min/1.73 m<sup>2</sup>, the dose of cefdinir should be 7 mg/kg (up to 300 mg) given once daily.</p><p><strong>Patients on Hemodialysis</strong></p><p>Hemodialysis removes cefdinir from the body. In patients maintained on chronic hemodialysis, the recommended initial dosage regimen is a 300-mg or 7-mg/kg dose every other day. At the conclusion of each hemodialysis session, 300 mg (or 7 mg/kg) should be given. Subsequent doses (300 mg or 7 mg/kg) are then administered every other day.</p><p><strong>Hepatic Impairment</strong></p><p>Dosage adjustments not required.</p><p><strong>Geriatric Patients</strong></p><p>No dosage adjustments except those related to renal impairment.<sup>1</sup> (See Renal Impairment under Dosage and Administration.)0</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                OMNICEF (cefdinir) is contraindicated in patients with known allergy to the cephalosporin class of antibiotics.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>WARNINGS</strong></p><p><strong>BEFORE THERAPY WITH OMNICEF (CEFDINIR) IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFDINIR, OTHER CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF CEFDINIR IS TO BE GIVEN TO PENICILLINSENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSSHYPERSENSITIVITY AMONG &beta;- LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. IF AN ALLERGIC REACTION TO CEFDINIR OCCURS, THE DRUG SHOULD BE DISCONTINUED. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.</strong></p><p><em>Clostridium difficile </em>associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including OMNICEF, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <em>C. difficile</em>.</p><p><em>C. difficile </em>produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of <em>C. difficile </em>cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p><p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <em>C. difficile</em>&nbsp;may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <em>C. difficile</em>, and surgical evaluation should be instituted as clinically indicated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Antacids (aluminum- or magnesium-containing)</em></p><p>Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%. Time to reach Cmax is also prolonged by 1 hour. There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir. If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.</p><p><em>Probenecid</em></p><p>As with other &beta;-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in AUC, a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination t&frac12;.</p><p><em>Iron Supplements and Foods Fortified With Iron</em></p><p>Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively. If iron supplements are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the supplement.</p><p>The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.</p><p>Concomitantly administered iron-fortified infant formula (2.2 mg elemental iron/6 oz) has no significant effect on cefdinir pharmacokinetics. Therefore, OMNICEF for Oral Suspension can be administered with iron-fortified infant formula.</p><p>There have been reports of reddish stools in patients receiving cefdinir. In many cases, patients were also receiving iron-containing products. The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.</p><p><strong>Drug/Laboratory Test Interactions</strong></p><p>A false-positive reaction for ketones in the urine may occur with tests using nitroprusside, but not with those using nitroferricyanide. The administration of cefdinir may result in a false-positive reaction for glucose in urine using Clinitest&reg;, Benedict&#39;s solution, or Fehling&#39;s solution. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix&reg; or Tes-Tape&reg;) be used. Cephalosporins are known to occasionally induce a positive direct Coombs&#39; test.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy: Teratogenic Effects: Pregnancy Category B.</p><p>Cefdinir was not teratogenic in rats at oral doses up to 1000 mg/kg/day (70 times the human dose based on mg/kg/day, 11 times based on mg/m2/day) or in rabbits at oral doses up to 10 mg/kg/day (0.7 times the human dose based on mg/kg/day, 0.23 times based on mg/m2/day). Maternal toxicity (decreased body weight gain) was observed in rabbits at the maximum tolerated dose of 10 mg/kg/day without adverse effects on offspring. Decreased body weight occurred in rat fetuses at &ge;100 mg/kg/day, and in rat offspring at &ge;32 mg/kg/day. No effects were observed on maternal reproductive parameters or offspring survival, development, behavior, or reproductive function.</p><p>There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p><p>Labor and Delivery:</p><p>Cefdinir has not been studied for use during labor and delivery.</p><p>Breast feeding:</p><p>Following administration of single 600 mg doses, cefdinir was not detected in human breast milk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical trials, 5093 adult and adolescent patients (3841 U.S. and 1252 non-U.S.) were treated with the recommended dose of cefdinir capsules (600 mg/day). Most adverse events were mild and self-limiting. No deaths or permanent disabilities were attributed to cefdinir. One hundred forty-seven of 5093 (3%) patients discontinued medication due to adverse events thought by the investigators to be possibly, probably, or definitely associated with cefdinir therapy. The discontinuations were primarily for gastrointestinal disturbances, usually diarrhea or nausea. Nineteen of 5093 (0.4%) patients were discontinued due to rash thought related to cefdinir administration.</p><p>In the U.S., the following adverse events were thought by investigators to be possibly, probably, or definitely related to cefdinir capsules in multiple-dose clinical trials (N = 3841 cefdinir-treated patients):</p><p><strong>ADVERSE EVENTS ASSOCIATED WITH CEFDINIR CAPSULES</strong></p><p><strong>U.S. TRIALS IN ADULT AND ADOLESCENT PATIENTS (N=3841)a</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Incidence &ge;1%</p></td><td><p>Diarrhea</p></td><td><p>15%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Vaginal moniliasis</p></td><td><p>4% of women</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Nausea</p></td><td><p>3%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Headache</p></td><td><p>2%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Abdominal pain</p></td><td><p>1%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Vaginitis</p></td><td><p>1% of women</p></td></tr><tr><td><p>Incidence &lt;1% but &gt;0.1%</p></td><td><p>Rash</p></td><td><p>0.9%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Dyspepia</p></td><td><p>0.7%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Flatulence</p></td><td><p>0.7%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Vomiting</p></td><td><p>0.7%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Abnormal stools</p></td><td><p>0.3%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Anorexia</p></td><td><p>0.3%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Constipation</p></td><td><p>0.3%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Dizziness</p></td><td><p>0.3%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Dry Mouth</p></td><td><p>0.3%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Asthenia</p></td><td><p>0.2%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Insomnia</p></td><td><p>0.2%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Leukorrhea</p></td><td><p>0.2% of women</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Moniliasis</p></td><td><p>0.2%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Pruritus</p></td><td><p>0.2%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Somnolence</p></td><td><p>0.2%</p></td></tr></tbody></table><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:423.4pt;height:341.45pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><sup>a</sup> 1733 males, 2108 females</p><p><strong>Postmarketing Experience:</strong></p><p>The following adverse experiences and altered laboratory tests, regardless of their relationship to cefdinir, have been reported during extensive postmarketing experience, beginning with approval in Japan in 1991: shock, anaphylaxis with rare cases of fatality, facial and laryngeal edema, feeling of suffocation, serum sickness- like reactions, conjunctivitis, stomatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, erythema multiforme, erythema nodosum, acute hepatitis, cholestasis, fulminant hepatitis, hepatic failure, jaundice, increased amylase, acute enterocolitis, bloody diarrhea, hemorrhagic colitis, melena, pseudomembranous colitis, pancytopenia, granulocytopenia, leukopenia, thrombocytopenia, idiopathic thrombocytopenic purpura, hemolytic anemia, acute respiratory failure, asthmatic attack, drug-induced pneumonia, eosinophilic pneumonia, idiopathic interstitial pneumonia, fever, acute renal failure, nephropathy, bleeding tendency, coagulation disorder, disseminated intravascular coagulation, upper GI bleed, peptic ulcer, ileus, loss of consciousness, allergic vasculitis, possible cefdinir-diclofenac interaction, cardiac failure, chest pain, myocardial infarction, hypertension, involuntary movements, and rhabdomyolysis.</p><p><strong>Cephalosporin Class Adverse Events:</strong></p><p>The following adverse events and altered laboratory tests have been reported for cephalosporin-class antibiotics in general:</p><p>Allergic reactions, anaphylaxis, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, renal dysfunction, toxic nephropathy, hepatic dysfunction including cholestasis, aplastic anemia, hemolytic anemia, hemorrhage, false-positive test for urinary glucose, neutropenia, pancytopenia, and agranulocytosis.</p><p>Pseudomembranous colitis symptoms may begin during or after antibiotic treatment (see section 4.4 Special warnings and precautions for use<strong>).</strong></p><p>Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced (see section 4.2 Posology and method of administration and 4.9 Overdose<strong>). </strong>If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.</p><p><strong><u>Reporting of suspected adverse reactions</u></strong></p><ul><li>&nbsp;&nbsp;<strong>Saudi Arabia:</strong></li></ul><p>&minus; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662 Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-</p><p>2334-2340. Toll free phone: 8002490000</p><p>E-mail:<u> npc.drug@sfda.gov.sa</u></p><p>Website: <u>www.sfda.gov.sa/npc</u></p><ul><li><strong>Other GCC States: </strong>Please contact the relevant competent authority.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Information on cefdinir overdosage in humans is not available. In acute rodent toxicity studies, a single oral 5600 mg/kg dose produced no adverse effects. Toxic signs and symptoms following overdosage with other &beta;- lactam antibiotics have included nausea, vomiting, epigastric distress, diarrhea, and convulsions.</p><p>Hemodialysis removes cefdinir from the body. This may be useful in the event of a serious toxic reaction from overdosage, particularly if renal function is compromised.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: third generation Cephalosporin, ATC code: J01DD15</p><p><u>Mechanism of action / Pharmacodynamic effects</u></p><p>Cefdinir is a third generation cephalosporin with a broad spectrum of activity against enteric gram-negative rods. Cefdinir is stable in the presence of some, but not all, b- lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins are susceptible to cefdinir. Cephalosporins work the same way as penicillins: they interfere with the peptidoglycan synthesis of the bacterial wall by inhibiting the final transpeptidation needed for the cross-links. This effect is bactericidal.</p><p>As with other cephalosporins, bactericidal activity of cefdinir results from inhibition of cell wall synthesis by acting on penicillin binding proteins (PBPs).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption:</strong></p><p><strong>Oral Bioavailability: </strong>Maximal plasma cefdinir concentrations occur 2 to 4 hours postdose following capsule or suspension administration. Plasma cefdinir concentrations increase with dose, but the increases are less than dose-proportional from 300 mg (7 mg/kg) to 600 mg (14 mg/kg). Following administration of suspension to healthy adults, cefdinir bioavailability is 120% relative to capsules. Estimated bioavailability of cefdinir capsules is 21% following administration of a 300 mg capsule dose, and 16% following administration of a 600 mg capsule dose. Estimated absolute bioavailability of cefdinir suspension is 25%.</p><p><strong>Effect of Food: </strong>The C<sub>max </sub>and AUC of cefdinir from the capsules are reduced by 16% and 10%, respectively, when given with a high-fat meal. The magnitude of these reductions is not likely to be clinically significant. Therefore, cefdinir may be taken without regard to food.</p><p>Cefdinir plasma concentrations and pharmacokinetic parameter values following administration of single 300 and 600 mg oral doses of cefdinir to adult subjects are presented in the following table:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4"><p>Mean (&plusmn;SD) Plasma Cefdinir Pharmacokinetic Parameter Values Following Administration of Capsules to Adult Subjects</p></td></tr><tr><td><p><strong>Dose</strong></p></td><td><p><strong>C<sub>max</sub>(mcg/mL)</strong></p></td><td><p><strong>t<sub>max</sub>(hr)</strong></p></td><td><p><strong>AUC(mcg.hr/mL)</strong></p></td></tr><tr><td><p>300 mg</p></td><td><p>1.60(0.55)</p></td><td><p>2.9(0.89)</p></td><td><p>7.05(2.17)</p></td></tr><tr><td><p>600 mg</p></td><td><p>2.87(1.01)</p></td><td><p>3.0(0.66)</p></td><td><p>11.1(3.87)</p></td></tr></tbody></table><p><strong>Multiple Dosing: </strong>Cefdinir does not accumulate in plasma following once- or twice-daily administration to subjects with normal renal function.</p><p><strong>Distribution:</strong></p><p>The mean volume of distribution (Vdarea) of cefdinir in adult subjects is 0.35 L/kg (&plusmn;0.29); in pediatric subjects (age 6 months-12 years), cefdinir Vdarea is 0.67 L/kg (&plusmn;0.38). Cefdinir is 60% to 70% bound to plasma proteins in both adult and pediatric subjects; binding is independent of concentration.</p><p><strong>Skin Blister: </strong>In adult subjects, median (range) maximal blister fluid cefdinir concentrations of 0.65 (0.33-1.1) and 1.1 (0.49-1.9) mcg/mL were observed 4 to 5 hours following administration of 300 and 600 mg doses, respectively. Mean (&plusmn;SD) blister Cmax and AUC (0-&infin;) values were 48% (&plusmn;13) and 91% (&plusmn;18) of corresponding plasma values.</p><p><strong>Tonsil Tissue: </strong>In adult patients undergoing elective tonsillectomy, respective median tonsil tissue cefdinir concentrations 4 hours after administration of single 300 and 600 mg doses were 0.25 (0.22-0.46) and 0.36 (0.22-0.80) mcg/g. Mean tonsil tissue concentrations were 24% (&plusmn;8) of corresponding plasma concentrations.</p><p><strong>Sinus Tissue: </strong>In adult patients undergoing elective maxillary and ethmoid sinus surgery, respective median sinus tissue cefdinir concentrations 4 hours after administration of single 300 and 600 mg doses were &lt;0.12 (&lt;0.12-0.46) and 0.21 (&lt;0.12-2.0) mcg/g. Mean sinus tissue concentrations were 16% (&plusmn;20) of corresponding plasma concentrations.</p><p><strong>Lung Tissue: </strong>In adult patients undergoing diagnostic bronchoscopy, respective median bronchial mucosa cefdinir concentrations 4 hours after administration of single 300 and 600 mg doses were 0.78 (&lt;0.06-1.33) and 1.14 (&lt;0.06-1.92) mcg/mL, and were 31% (&plusmn;18) of corresponding plasma concentrations. Respective median epithelial lining fluid concentrations were 0.29 (&lt;0.3-4.73) and 0.49 (&lt;0.3-0.59) mcg/mL, and were 35% (&plusmn;83) of corresponding plasma concentrations.</p><p><strong>Middle Ear Fluid: </strong>In 14 pediatric patients with acute bacterial otitis media, respective median middle ear fluid cefdinir concentrations 3 hours after administration of single 7 and 14 mg/kg doses were 0.21 (&lt;0.09-0.94) and 0.72 (0.14-1.42) mcg/mL. Mean middle ear fluid concentrations were 15% (&plusmn;15) of corresponding plasma concentrations.</p><p><strong>CSF: </strong>Data on cefdinir penetration into human cerebrospinal fluid are not available.</p><p>&nbsp;</p><p><strong>Metabolism and Excretion:</strong></p><p>Cefdinir is not appreciably metabolized. Activity is primarily due to parent drug. Cefdinir is eliminated principally via renal excretion with a mean plasma elimination half-life (t1/2) of 1.7 (&plusmn;0.6) hours. In healthy subjects with normal renal function, renal clearance is 2.0 (&plusmn;1.0) mL/min/kg, and apparent oral clearance is 11.6 (&plusmn;6.0) and 15.5 (&plusmn;5.4) mL/min/kg following doses of 300 and 600 mg, respectively. Mean percent of dose recovered unchanged in the urine following 300 and 600 mg doses is 18.4% (&plusmn;6.4) and 11.6% (&plusmn;4.6), respectively. Cefdinir clearance is reduced in patients with renal dysfunction. Because renal excretion is the predominant pathway of elimination, dosage should be adjusted in patients with markedly compromised renal function or who are undergoing hemodialysis (see 4.2 Posology and method of administration).</p><p><strong>Special Populations:</strong></p><p><strong>Patients with Renal Insufficiency: </strong>Cefdinir pharmacokinetics were investigated in 21 adult subjects with varying degrees of renal function. Decreases in cefdinir elimination rate, apparent oral clearance (CL/F), and renal clearance were approximately proportional to the reduction in creatinine clearance (CLcr). As a result, plasma cefdinir concentrations were higher and persisted longer in subjects with renal impairment than in those without renal impairment. In subjects with CLcr between 30 and 60 mL/min, C<sub>max</sub> and t1/2 increased by approximately 2-fold and AUC by approximately 3-fold. In subjects with CLcr &lt;30 mL/min, C<sub>max</sub> increased by approximately 2-fold, t1/2 by approximately 5-fold, and AUC by approximately 6-fold. Dosage adjustment is recommended in patients with markedly compromised renal function (creatinine clearance &lt;30 mL/min; see section 4.2 Posology and method of administration).</p><p><strong>Hemodialysis: </strong>Cefdinir pharmacokinetics were studied in 8 adult subjects undergoing hemodialysis. Dialysis (4 hours duration) removed 63% of cefdinir from the body and reduced apparent elimination t1/2 from 16 (&plusmn;3.5) to 3.2 (&plusmn;1.2) hours. Dosage adjustment is recommended in this patient population (see 4.2 Posology and method of administration).</p><p><strong>Hepatic Disease: </strong>Because cefdinir is predominantly renally eliminated and not appreciably metabolized, studies in patients with hepatic impairment were not conducted. It is not expected that dosage adjustment will be required in this population.</p><p><strong>Geriatric Patients: </strong>The effect of age on cefdinir pharmacokinetics after a single 300 mg dose was evaluated in 32 subjects 19 to 91 years of age. Systemic exposure to cefdinir was substantially increased in older subjects (N=16), C<sub>max</sub> by 44% and AUC by 86%. This increase was due to a reduction in cefdinir clearance. The apparent volume of distribution was also reduced, thus no appreciable alterations in apparent elimination t1/2 were observed (elderly: 2.2 &plusmn; 0.6 hours vs young: 1.8 &plusmn; 0.4 hours). Since cefdinir clearance has been shown to be primarily related to changes in renal function rather than age, elderly patients do not require dosage adjustment unless they have markedly compromised renal function (creatinine clearance &lt;30 mL/min, see Patients with Renal Insufficiency, above).</p><p><strong>Gender and Race: </strong>The results of a meta-analysis of clinical pharmacokinetics (N=217) indicated no significant impact of either gender or race on cefdinir pharmacokinetics.</p><p><strong>Microbiology:</strong></p><p>As with other cephalosporins, bactericidal activity of cefdinir results from inhibition of cell wall synthesis. Cefdinir is stable in the presence of some, but not all, &beta;-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins are susceptible to cefdinir.</p><p>Cefdinir has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in (4.1 Therapeutic indications).</p><p><strong>Aerobic Gram-Positive Microorganisms:</strong></p><p>Staphylococcus aureus (including &beta;-lactamase producing strains)</p><p>NOTE: Cefdinir is inactive against methicillin-resistant staphylococci.</p><p>Streptococcus pneumoniae (penicillin-susceptible strains only)</p><p>Streptococcus pyogenes</p><p><strong>Aerobic Gram-Negative Microorganisms:</strong></p><p>Haemophilus influenzae (including &beta;-lactamase producing strains)</p><p>Haemophilus parainfluenzae (including &beta;-lactamase producing strains)</p><p>Moraxella catarrhalis (including &beta;-lactamase producing strains)</p><p>The following in vitro data are available, <strong>but their clinical significance is unknown</strong>.</p><p>Cefdinir exhibits in vitro minimum inhibitory concentrations (MICs) of 1 mcg/mL or less against (&ge;90%) strains of the following microorganisms; however, the safety and effectiveness of cefdinir in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled clinical trials.</p><p><strong>Aerobic Gram-Positive Microorganisms:</strong></p><p>Staphylococcus epidermidis (methicillin-susceptible strains only)</p><p>Streptococcus agalactiae</p><p>Viridans group streptococci</p><p>NOTE: Cefdinir is inactive against Enterococcus and methicillin- resistant Staphylococcus species.</p><p><strong>Aerobic Gram-Negative Microorganisms:</strong></p><p>Citrobacter diversus</p><p>Escherichia coli</p><p>Klebsiella pneumoniae</p><p>Proteus mirabilis</p><p>NOTE: Cefdinir is inactive against Pseudomonas and Enterobacter species.</p><p><strong>Susceptibility Tests:</strong></p><p><strong>Dilution Techniques: </strong>Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method(1) (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of cefdinir powder. The MIC values should be interpreted according to the following criteria:</p><p>For organisms other than Haemophilus spp. and Streptococcus spp.:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>MIC (mcg/mL)</strong></p></td><td><p><strong>Interpretation</strong></p></td></tr><tr><td><p>&le;1</p></td><td><p>Susceptible (S)</p></td></tr><tr><td><p>2</p></td><td><p>Intermediate (I)</p></td></tr><tr><td><p>&ge;4</p></td><td><p>Resistant (R)</p></td></tr></tbody></table><p>For Haemophilus spp:<sup>a</sup></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>MIC (mcg/mL)</strong></p></td><td><p><strong>Interpretationb</strong></p></td></tr><tr><td><p>&le;1</p></td><td><p>Susceptible (S)</p></td></tr><tr><td colspan="2"><p><sup>a</sup> These interpretive standards are applicable only to broth microdilution susceptibility tests withHaemophilus spp. using Haemophilus Test Medium (HTM).<sup>(1)</sup></p><p><sup>b</sup> The current absence of data on resistant strains precludes defining any results other than &ldquo;Susceptible&rdquo;. Strains yielding MIC results suggestive of a &ldquo;nonsusceptible&rdquo; category should be submitted to a reference laboratory for further testing.</p></td></tr></tbody></table><p>For Streptococcus spp:</p><p>Streptococcus pneumoniae that are susceptible to penicillin (MIC &le;0.06 mcg/mL), or streptococci other than S. pneumoniae that are susceptible to penicillin (MIC &le;0.12 mcg/mL), can be considered susceptible to cefdinir. Testing of cefdinir against penicillin- intermediate or penicillin-resistant isolates is not recommended. Reliable interpretive criteria for cefdinir are not available.</p><p>A report of &quot;Susceptible&quot; indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentration usually achievable. A report of &quot;Intermediate&quot; indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of &quot;Resistant&quot; indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.</p><p>Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of laboratory procedures. Standard cefdinir powder should provide the following MIC values:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Microorganism</strong></p></td><td><p><strong>MIC Range (mcg/mL)</strong></p></td></tr><tr><td><p>Escherichia coli ATCC 25922</p></td><td><p>0.12-0.5</p></td></tr><tr><td><p>Haemophilus influenzae ATCC 49766c</p></td><td><p>0.12-0.5</p></td></tr><tr><td><p>Staphylococcus aureus ATCC 29213</p></td><td><p>0.12-0.5</p></td></tr><tr><td colspan="2"><p><sup>c</sup> This quality control range is applicable only to H. influenzae ATCC 49766 tested by a</p><p>broth microdilution procedure using HTM.<sup>(1)</sup></p></td></tr></tbody></table><p><strong>Diffusion Techniques: </strong>Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure(2) requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 5 mcg cefdinir to test the susceptibility of microorganisms to cefdinir.</p><p>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 5 mcg cefdinir disk should be interpreted according to the following criteria:</p><p>For organisms other than Haemophilus spp. and Streptococcus spp:<sup>d</sup></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Zone Diameters (mm)</strong></p></td><td><p><strong>Interpretation</strong></p></td></tr><tr><td><p>&ge;20</p></td><td><p>Susceptible (S)</p></td></tr><tr><td><p>17-19</p></td><td><p>Intermediate (I)</p></td></tr><tr><td><p>&le;16</p></td><td><p>Resistant (R)</p></td></tr><tr><td colspan="2"><p><sup>d</sup> Because certain strains of Citrobacter, Providencia, and Enterobacter spp. have been reported to give false susceptible results with the cefdinir disk, strains of these genera should not be tested and reported with this disk.</p></td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td></tr></tbody></table><p>For Haemophilus spp:<sup>e</sup></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Zone Diameters (mm)</strong></p></td><td><p><strong>Interpretation</strong>f</p></td></tr><tr><td><p>&ge;20</p></td><td><p>Susceptible (S)</p></td></tr><tr><td colspan="2"><p><sup>e</sup> These zone diameter standards are applicable only to tests with Haemophilus spp. using HTM.<sup>(2)</sup></p><p><sup>f</sup> The current absence of data on resistant strains precludes defining any results other than &ldquo;Susceptible&rdquo;. Strains yielding MIC results suggestive of a &ldquo;nonsusceptible&rdquo; category should be submitted to a reference laboratory for further testing.</p></td></tr></tbody></table><p>For Streptococcus spp:</p><p>Isolates of Streptococcus pneumoniae should be tested against a 1 mcg oxacillin disk. Isolates with oxacillin zone sizes &ge;20 mm are susceptible to penicillin and can be considered susceptible to cefdinir. Streptococci other than S. pneumoniae should be tested with a 10 unit penicillin disk. Isolates with penicillin zone sizes &ge;28 mm are susceptible to penicillin and can be considered susceptible to cefdinir.</p><p>As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms to control the technical aspects of laboratory procedures. For the diffusion technique, the 5 mcg cefdinir disk should provide the following zone diameters in these laboratory quality control strains:</p><table border="1" cellspacing="0" cellpadding="0" style="width:727px"><tbody><tr><td><p><strong>Organism</strong></p></td><td style="width:422px"><p><strong>Zone Diameter (mm)</strong></p></td></tr><tr><td><p>Escherichia coli ATCC 25922</p></td><td style="width:422px"><p>24-28</p></td></tr><tr><td><p>Haemophilus influenzae ATCC 49766<sup>g</sup></p></td><td style="width:422px"><p>24-31</p></td></tr><tr><td><p>Staphylococcus aureus ATCC 25923</p></td><td style="width:422px"><p>25-32</p></td></tr><tr><td colspan="2" style="width:724px"><p><sup>g</sup> This quality control range is applicable only to testing of H. influenzae ATCC 49766 using HTM.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><ul><li>Carmellose Calcium</li><li>Treated Magnesium Stearate</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25 ͦ C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pack of 10 Capsules</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirement.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Jazeera Pharmaceutical Industries
 Jeser Heet, after 3rd industrial Zone
Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                17 November 2013
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>